



## MITHRA PHARMACEUTICALS RELEASES 2015 ANNUAL REPORT AND INVITATION TO ITS ORDINARY GENERAL SHAREHOLDER'S MEETING

**Liège, Belgium 19 April 2016** – Mithra Pharmaceuticals is pleased to announce the publication of its 2015 Annual Report and the invitation for its Ordinary General Shareholder's meeting.

### Annual Report

The Annual Report which outlines Mithra's achievements in 2015 includes the following information:

- Overview of Mithra's R&D pipeline and letter to shareholders;
- Highlights of Mithra's strategy and outlook for 2016;
- Corporate governance section;
- Financial statements and notes.

**François Fornieri, CEO Mithra Pharmaceuticals:** *"Our 2015 Annual Report highlights the significant milestones Mithra achieved in 2015, a pivotal year in Mithra's history. It also underlines the efforts and commitment of our teams to support the evolution of Mithra, and more specifically the R&D pillar development of the company."*

This Annual Report is the first Annual Report released by Mithra since its IPO in June 2015. Mithra releases its Annual Report in English and French. In case of interpretation differences, the English version will prevail.

The report is available in English and French and can be downloaded on the website [investors.mithra.com](http://investors.mithra.com) as a PDF file.

### Ordinary General Shareholder's meeting

The Ordinary General Shareholder's meeting of Mithra Pharmaceuticals will be held on 19<sup>th</sup> May 2016 at 17:00 PM (CEST) in Liège (Belgium). Mithra Pharmaceuticals is pleased to invite its shareholders.

The notice for the Ordinary General Shareholder's meeting including a description of the formalities to participate in the Meeting is available on the website [investors.mithra.com](http://investors.mithra.com).

## Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

## For more information, please contact:

### Press

#### **Julie Dessart**

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

[press@mithra.com](mailto:press@mithra.com)

### Investor Relations

#### **François Fornieri, CEO**

+32 4 349 28 22

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

## About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](http://investors.mithra.com)